BSEBoard Meeting2 Nov 2026 · 2 Nov 2026, 04:20 pm
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve unaudited standalone and consolidated financials results for the quarter and half year ended 30th September, 2026
Kilitch Drugs India Ltd · 524500
✦ AI SummaryResults
Kilitch Drugs India Ltd has scheduled a board meeting on 06/11/2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Kilitch Drugs India Ltd - 524500 - Board Meeting Intimation for Consider And Approval Of Unaudited Standalone And Consolidated Financials Results For The Quarter And Half Year Ended 30Th September, 2026
Attachments (1)
📄pdf
Download →
154d91f7-4c64-4a68-97cf-19c208374345.pdf
View document text
Kilitch Drugs (India) Ltd. KI
2™ November, 2026
To, To,
The Manager - Corporate Relationship The Manager - Corporate Compliance
Dept. National Stock Exchange of India Ltd
BSE Limited Exchange Plaza, Plot No.C-1,
P. J. Towers, Dalal Street G Block, BKC, Bandra (E),
Fort, Mumbai - 400 001 Mumbai 400 051
Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH
Sub: Intimation of the Board Meeting
Dear Sir,
Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held
on Friday, 6" November, 2026 inter-alia to consider and approve the unaudited Financial Results
(Standalone and Consolidated) of the Company for the quarter and half year ended 30" September, 2026.
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider
Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2"¢ April,
2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2™ April, 2019 issued by NSE
and Company’s code of conduct for Prevention of Insider Trading, the Trading Window has been closed
with effect from 1*' October, 2026 and will re-open 48 hours after said financial results are disclosed to the
Stock Exchanges.
We request you to kindly take the same on record and acknowledge the receipt.
Thanking you,
Yours Faithfully,
For Kilitch Drugs (India) Limited
Mukund Mehta
Managing Director
DIN: 00147876
4 ISO
ly ca
139408051::22000038 WHO CEe RTIFIED
& et
EES ono.
Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. « Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658
Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra.
« CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.com « Website : www.kilitch.com